Skip to main content
. 2018 Jan 23;7:1–14. doi: 10.2147/ITT.S134834

Figure 1.

Figure 1

PS-targeting antibodies interact with exposed PS in the tumor microenvironment to activate immune cells.(p)(p)Notes: PS exposure in the tumor microenvironment activates PS receptors in immune cells and causes these cells to adopt an immunosuppressive phenotype. PS-targeting antibodies 2aG4, 3G4, bavituximab, 1N11, and mch1N11 bind exposed PS via β2GP1. Binding of the PS-targeting complex blocks the interaction between PS and the PS receptors on immune cells and activates these cells via their FcγR.(p)(p)Abbreviations: ADCC, antibody-dependent cell-mediated cytotoxicity; β2GP1, beta 2 glycoprotein-1; FcγR, Fc gamma receptor; IL, interleukin; MDSC, myeloid-derived suppressor cell; PS, phosphatidylserine; TAMs, Tyro3, Axl, Mer receptor tyrosine kinases; TIMs, transmembranes, immunoglobulins, and mucins; TGF, transforming growth factor; TNF, tumor necrosis factor.